Lazzat Begimbekova

Lazzat Begimbekova

Auto-generated profile, based on publicly available information

Lazzat Begimbekova

Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2025 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
JKJayendra Kumar
Jayendra Kumar
TMTolepbergenova M.
Tolepbergenova M.
AMAbdugani Musayev
Abdugani Musayev
ADAizhan Danyshbayeva
Aizhan Danyshbayeva
LBLazzat Begimbekova
Lazzat Begimbekova
SSShamim Shamim
Shamim Shamim

15 March 2024
Verified
Journal Article
Open access
LAL.R. Agababyan
L.R. Agababyan
LBL.M. Begimbekova
L.M. Begimbekova
LVL.а. Vasylchenko
L.а. Vasylchenko
FGF.A. Gafurova
F.A. Gafurova
MGMa. Gegechkori
Ma. Gegechkori
OYO.G. Yashina
O.G. Yashina
On November 23, 2023, the V International Forum of Experts on Menopausal Hormone Therapy (MHT) was held. The Expert Council’s working group included leading experts in the field of endocrine gynaecology and related areas from Azerbaijan, Armenia, Georgia, Kazakhstan, Moldova, Uzbekistan, and Ukraine.The Forum experts noted the importance of dialogue and understanding between doctor and patient, the need for interdisciplinary integration between doctors of those specialties that deal with women’s health issues. Close cooperation with related specialists who provide care to women is necessary, as they are often the ones who encounter the first manifestations of menopause in patients and can therefore refer them to an obstetrician-gynaecologist in a timely manner. The experts reviewed the issue of cardiovascular risk and MHT and determined the following benefit/risk ratio for the cardiovascular effects of MHT:• MHT is not recommended for women at high cardiovascular risk or with previous cardiovascular disease;• MHT may reduce the risk of CVD-related all-cause death in women < 60 years of age and with menopause of up to 10 years;• timely initiation of MHT (in women under 60 years of age or within 10 years of menopause) has the greatest cardiovascular health benefits.The forum updated the Algorithm for prescribing MHT in premature and early menopause and addressed the management of women with polycystic ovary syndrome in menopause. Since the majority of women with this syndrome are overweight and obese, they should use the most metabolically neutral drugs, i.e. those containing didrogesterone or progesterone, for MHT. MHT with didrogesterone has a favourable safety profile in relation to the most common risks of MHT: does not increase the risk of breast cancer and venous thromboembolism, has a favourable safety profile with respect to the endometrium, and does not affect metabolism.

17 April 2026
Verified
Journal Article
Open access
TTT.F. Tatarchuk
T.F. Tatarchuk
NPN.Y. Pedachenko
N.Y. Pedachenko
GGGalina Grebennikova
Galina Grebennikova
OGO.L. Gromova
O.L. Gromova
DKDilrabo Kayumova
Dilrabo Kayumova
TUT.M. Ukybasova
T.M. Ukybasova
The VII International Forum of Experts on Menopausal Hormone Therapy (MHT) was held in Kyiv on November 18, 2025. The modern approach to the MHT prescription is not to resolve the issue of its appropriateness, but to choose the optimal form for a particular woman. Different routes of hormone administration have different pharmacokinetic properties and effects on metabolism, the coagulation system, and women’s somatic health. The recommendations of the European Menopause and Andropause Society emphasize the appropriateness of using combined MHT to improve the glycemic profile and delay the development of diabetes mellitus, with a preference for metabolically neutral progestogens – progesterone and dydrogesterone.Transdermal estrogens enter the systemic circulation directly, minimizing the effect on the liver and coagulation, which makes them the method of choice for women with an increased risk of venous thrombosis, obesity, or hypertriglyceridemia. At the same time, the effectiveness of transdermal MHT is characterized by significant interindividual variability.MHT is an effective antiresorptive method for the prevention of osteoporosis and fractures. Clinical studies demonstrate a significant increase in bone mineral density and a reduction in the risk of fractures with the use of MHT, particularly the combination of estradiol and dydrogesterone. Timely initiated MHT (within the first 10 years after menopause) is also associated with a decrease in all-cause mortality, cardiovascular complications, and neurodegenerative diseases. The individual choice of the form of MHT is a key factor in its safety and clinical efficacy.Particular attention should be paid to oncological safety, particularly the risk of breast cancer, when selecting MHT in patients using a levonorgestrel-releasing intrauterine system. Data from systematic reviews and meta-analyses indicate that the use of estrogens does not increase this risk, while it largely depends on the type of progestogen. Progesterone and dydrogesterone have the most favorable safety profile for the breast compared with synthetic gestagens, which is confirmed by the results of large-scale studies.Psychoemotional and sexual disorders (anxiety, depression, sleep disorders, and decreased libido) are common in perimenopause and are largely due to systemic estrogen deficiency, which affects neurometabolic, vascular, and neuroendocrine homeostasis. The high frequency of these disorders justifies the need for comprehensive diagnostic assessment and individualized MHT in perimenopausal women.